Live
Novartis Healthcare Private Ltd (NHPL) has announced the launch of Scapho 150 mg to treat moderate to severe plaque psoriasis in adult patients.
The company has said in a statement that Scapho or Secukinumab, an injectable medicine, has been approved by the Drug Controller General of India (DCGI).
And added that this approval marks a significant milestone in the treatment of psoriasis providing a new and important first-line biologic treatment option for its patients, who are candidates for systemic therapy.
